Clinical Report: Disease-Specific Mortality in Barrett's Esophagus Neoplasia

Overview

This study evaluates disease-specific mortality (DSM) in patients with high-grade dysplasia (HGD) or low-risk T1 esophageal adenocarcinoma (EAC) undergoing endoscopic eradication therapy (EET). It highlights the long-term outcomes and complications associated with EET in this patient population.

Background

Esophageal cancer, particularly esophageal adenocarcinoma, has a poor prognosis, with a low 5-year survival rate. Barrett's esophagus significantly increases the risk of developing EAC, making early detection and intervention critical. Endoscopic surveillance and treatment strategies are essential for managing patients with Barrett's esophagus to improve outcomes.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The study focuses on the incidence of disease-specific mortality in patients with HGD or low-risk T1 EAC undergoing EET.
• Endoscopic eradication treatment is used with curative intent for HGD or T1 EAC without high-risk features.
• Long-term outcomes of patients with early Barrett's esophagus-related neoplasia have been under-reported.
• Previous studies reported 5-year survival rates ranging from 73% to 87.5% for similar patient populations.
• Rates of recurrence of EAC after 10 years are reported as 4.1%.

Clinical Implications

The findings emphasize the importance of monitoring disease-specific mortality in patients undergoing EET for Barrett's esophagus-related neoplasia. Clinicians should consider the long-term outcomes and potential complications associated with endoscopic interventions.

Conclusion

This study provides valuable insights into the long-term outcomes of patients with Barrett's esophagus-related neoplasia treated with endoscopic therapy, highlighting the need for ongoing surveillance and evaluation of treatment effectiveness.

Related Resources & Content

1. Surgical Endoscopy, 2024 -- A prospective cohort study evaluating disease-specific mortality in patients with early-stage Barrett’s esophagus-related neoplasia following endoscopic therapy
2. Journal of Gastrointestinal Surgery — Endoscopic Resection Alone for Early Neoplasia in Barrett's Esophagus: Long-Term Mortality and Endoscopic Observations
3. Journal of Gastroenterology — Changes in Protein Expression and Spliceosome Pathway Function During the Development of Barrett’s Carcinogenesis
4. Surgical Endoscopy — Factors Influencing Adverse Outcomes Following Endoscopic Intervention for Clinical T1a Esophageal Cancer
5. Journal of Gastroenterology — Incidence of Additional Primary Cancers in Patients with Clinical T1bN0 Esophageal Squamous Cell Carcinoma Following Definitive Treatment: An Extended Analysis of the JCOG0502 Trial
6. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia
7. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
8. Radiofrequency Ablation in Barrett's Esophagus with Dysplasia | New England Journal of Medicine
9. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial - PubMed
10. A prospective cohort study evaluating disease-specific mortality in patients with early-stage Barrett’s esophagus-related neoplasia following endoscopic therapy | Surgical Endoscopy | Springer Nature Link
11. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Neoplasia - ScienceDirect
12. https://academic.oup.com/dote/article/37/6/doae012/7612637